CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Quidel Corp. has completed its acquisition of BioHelix Corp.
According to terms of the deal, Quidel will pay BioHelix shareholders $10 million in cash, plus additional amounts in connection with an R&D earn-out based on the completion of a designated number of assays and a commercial earn-out dependent on product sales over a defined period.
With the acquisition of BioHelix, Quidel plans to accelerate development of its AmpliVue isothermal assays and decrease the associated manufacturing costs for those assays. Quidel sells the AmpliVue C. difficile assay, which received FDA clearance in December 2012.
Quidel will operate BioHelix as a wholly owned subsidiary.
Quidel Corp., 858-552-1100
BioHelix Corp., 928-927-5056